The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...

Annexon (ANNX) presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

The primary endpoint, GBS-Disability Scale, showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being in a ...

Also Read: Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of ...

He says “the scale of the challenge to the NHS is huge ... how lethal it is or how likely it is to lead to severe disability and whether lockdown would actually work.” ...